Leading Clinical Research Innovator, Amy Abernethy, M.D., Ph.D., Joins insitro Board of Directors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company’s board of directors. Dr. Abernethy, who has dedicated her career to transforming clinical development to drive innovation for patients, brings deep expertise having held a number of leadership roles in biotech, drug policy, and as a former practicing hematologist-oncologist and palliative medicine physic
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks